PsO is a chronic immune-mediated inflammatory skin disease characterized by impaired keratinocyte proliferation and differentiation. Deucravacitinib is a first-in-class TYK2 inhibitor approved for the treatment of moderate-to-severe PsO. At a recent symposium chaired by Professor Chan, Hin-Lee Henry, Professor April Armstrong presented the 4-year efficacy and safety data of deucravacitinib from the long-term extension of the POETYK trial programs which underscored the efficacy of deucravacitinib in difficult-to-treat areas such as the scalp. In addition, Dr. Guan, Xin and Dr. Zhang, Zhen-Ying also shared their firsthand clinical experience in managing different PsO patient subgroups with deucravacitinib.

Psoriasis is an immune-mediated inflammatory disease which has been found to influence the hormone levels of pregnant women, with up to 23% of patients experiencing exacerbation during pregnancy and 65% experiencing worsening conditions after delivery.1 Additionally, psoriasis is associated with und

Chronic disease management could be challenging logistically due to commitment and location, especially under the prevailing Coronavirus disease 2019 (COVID-19) pandemic.¹ This brings in the role of telemedicine, which allows patients to receive healthcare services remotely and efficiently, thus fac

Methotrexate is a multi-acting systemic antipsoriatic drug which simultaneously inhibits purine and pyrimidine synthesis, nitric oxide production and the transcription factor nuclear-factor kappa B (NFĸB) which is an inducible transcription factor for the production of pro-inflammatory cytokines and

As suggested by the observational studies from Italy and France presented at the Virtual Annual Congress of the European Academy of Dermatology and Venereology, biologic therapy for psoriasis may be protective to infected patients against severe and fatal COVID-19 although such protective benefit do

Experts of dermatology and related specialties from the Greater Bay Area gathered for the IL-17 summit. With the honor to have Professor Huang Zheng-Ming to give the opening speech, experts shared their insight and latest

Secukinumab, a fully human monoclonal antibody that selectively targets IL-17A, was the first drug in its class to receive approval for use in patients with ankylosing spondylitis (AS).^1,2 Back in 2016, the U.S. Food and Drug